Targeting cAMP signaling compartments in iPSC-derived models of cardiovascular disease

Curr Opin Pharmacol. 2023 Jul 13;71:102392. doi: 10.1016/j.coph.2023.102392. Online ahead of print.ABSTRACTAdenosine 3',5'-cyclic monophosphate (cAMP) acts as a second messenger that is involved in the regulation of a plethora of processes. The activation of cAMP signaling in defined compartments is critical for cells to respond to an extracellular stimulus in a specific manner. Rapid advances in the field of human induced pluripotent stem cells (iPSCs) reflect their great potential for cardiovascular disease modeling, drug screening, regenerative and precision medicine. This review discusses cAMP signaling in iPSC-derived cardiovascular disease models, and the prospects of using such systems to elucidate disease mechanisms, drug actions and to identify novel drug targets for the treatment of cardiovascular diseases with unmet medical need, such as hypertension and heart failure.PMID:37453312 | DOI:10.1016/j.coph.2023.102392
Source: Current Opinion in Pharmacology - Category: Drugs & Pharmacology Authors: Source Type: research